In a patient with CKD and LDL-C above target despite a statin, when should I refer for non-statin intensification?
Optimise the statin first, then refer for non-statin add-on if LDL-C remains above target on maximal tolerated therapy or if escalation is limited by CKD severity/intolerance. In CKD, referral is more justified when the patient is very high ASCVD risk, has possible familial hypercholesterolaemia, or may need injectable
How should cumulative torsades risk be assessed in HF patients taking amiodarone or other QT-active drugs?
In heart failure (HF) patients on amiodarone or other QT-active drugs, assess torsades de pointes (TdP) risk as cumulative rather than drug-specific: combine baseline substrate, current QTc, electrolytes/renal function, bradycardia, and the total QT-drug burden. HF itself is a recognized TdP risk factor, and risk rises
How should finerenone be layered with RAAS blockade, loop diuretics, and SGLT2 inhibitors without excessive hyperkalaemia?
Assuming adult patients with T2D + albuminuric CKD (the evidence-based indication for finerenone), the safest sequence is: 1. Maximise tolerated single-agent RAAS blockade with either an ACE inhibitor or an ARB — not dual ACEi+ARB. 2. Add an SGLT2 inhibitor early if eligible, because it is guideline-based cardiorenal t
Why can eGFR slope and albuminuria give different impressions of renal benefit?
eGFR slope and albuminuria reflect different biological dimensions of CKD, so they do not always move in parallel and may suggest different magnitudes—or even directions—of renal benefit. Albuminuria mainly tracks glomerular barrier injury/hemodynamic stress, whereas eGFR slope reflects the net change in filtration ove
What evidence gap should be discussed before using semaglutide specifically for post-ACS risk reduction?
The key evidence gap is that semaglutide has not been tested in a dedicated randomized trial started during the early post-ACS period specifically to reduce recurrent ischemic events after ACS. The major semaglutide cardiovascular outcome trials either excluded recent acute coronary/cerebrovascular events or enrolled b
